acumenpharm.com (ABOS) Year-over-year earnings per share growth for the last twelve months
Acumen Pharmaceuticals (ABOS) leverages powerful scientific potential to develop antibodies against neurotoxins. Business stability is underpinned by extensive research into toxic oligomers. Current clinical trials are creating negative operating leverage. The quarterly EPS trend visualizes these processes, and the value of 19.70 reflects this status, capturing current investor expectations regarding earnings per share.
Acumen Pharmaceuticals, Inc (ABOS) - metric breakdowns and financial figures
- share price and expert price forecast:
- market capitalization details:
- book capitalization data:
- debt and solvency information:
Total Debt to Capital Acumen Pharmaceuticals|ABOS - Long-Term Debt to Capital Coefficient|Short-Term Debt to Capital Acumen Pharmaceuticals|ABOS - Company Aggregate Debts|Debt to Book Capitalization Ratio Acumen Pharma|ABOS - Company Long-Term Loans and Borrowings|Company Short-Term Debt Acumen Pharmaceuticals|Quick Ratio acumenpharm.com
- earnings and valuation multiples information:
ABOS - Net Profit|Projected Future Earnings Acumen Pharmaceuticals|ABOS - Price to Earnings Ratio|Forward P/E Multiple Acumen Pharma|ABOS - Price to Earnings Adjusted for Growth Rate|Enterprise Value to EBITDA Ratio Acumen Pharma|ABOS - Operating profit EBITDA|Net earnings per share for the last 12 months Acumen Pharmaceuticals|ABOS - Earnings per share for the last four quarters|Quarterly EPS earnings growth acumenpharm.com|ABOS - Expected net earnings per share growth this year|Earnings growth forecast for next year Acumen Pharmaceuticals
Initial company analysis:Acumen Pharmaceuticals
This indicator measures quarterly net income per share dynamics, allowing investors to assess the business's actual resilience to market shocks and avoid overpaying for the asset. By analyzing the quarterly EPS growth vector, one can confirm the stability of Acumen Pharmaceuticals (ABOS), whose Alzheimer's therapy developments are shielded from geopolitical risks and trade restrictions by their humanitarian status.
Who Acumen Pharmaceuticals competes with
BIIB: Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Neurocrine (NBIX)|Year-over-year earnings per share growth for the last twelve months Regencell|Year-over-year earnings per share growth for the last 12 months AXSM (Axsome Corp)|Year-over-year net earnings per share growth for the last 12 months ACAD (ACADIA Pharmaceuticals)|XENE (xenon-pharma.com) - Year-over-year earnings per one share growth for the last 12 months|Year-over-year earnings per share growth for the last twelve months Viking Therapeutics, Inc. VKTX|SUPN (Supernus Pharmaceuticals, Inc.) - Year-over-year net earnings per share trend for the last twelve months|Catalyst Pharmaceuticals Inc - Quarterly EPS earnings growth|Year-over-year earnings per one share growth for the last 12 months DNLI (Denali Corp)|HRMY: Quarterly EPS earnings growth|biohavenpharma.com (BHVN) - Quarterly EPS earnings growth|Year-over-year earnings per share growth for the last twelve months Amylyx Pharmaceuticals, Inc.|TRVI: Year-over-year earnings per one share growth for the last 12 months|Year-over-year earnings per share growth for the last twelve months Praxis Medicines (PRAX)|Year-over-year net earnings per share growth for the last 12 months Anavex Life Sciences Corp AVXL|Quarterly EPS earnings growth CBLL (CeriBell, Inc.)|Quarterly EPS earnings growth prothena.com PRTA|Alector Therapeutics - Quarterly EPS earnings growth|Annexon Biosciences (ANNX) - Year-over-year net earnings per share growth for the last 12 months|OMER: Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Neurogene Therapeutics (NGNE)|Year-over-year net earnings per share growth for the last 12 months ACIU|Quarterly EPS earnings growth voyagertherapeutics.com|Year-over-year net earnings per share growth for the last 12 months NMRA (Neumora Therapeutics, Inc.)|Year-over-year earnings per share growth rate for the last twelve months SCLX|Quarterly EPS earnings growth TVGN (Tevogen Bio Holdings, Inc.)|Year-over-year net earnings per share change for the last twelve months Alpha Cognition Inc (ACOG)|Cognition Therapeutics, Inc. - Quarterly EPS earnings growth|inhibikase.com (IKT) - Year-over-year net earnings per share growth for the last 12 months|SAVA: Quarterly EPS earnings growth|Assertio (ASRT) - Quarterly EPS earnings growth|Year-over-year earnings per share growth for the last twelve months Coya Therapeutics Inc|Year-over-year earnings per share growth for the last twelve months VTGN|Year-over-year earnings per share growth for the last twelve months Ovid Therapeutics Inc. (OVID)|Year-over-year net earnings per share change for the last twelve months cervomed.com|Quarterly EPS earnings growth ATHE (Alterity Therapeutics Limited)|Quarterly EPS earnings growth Clene Inc CLNN|PepGen Corp - Quarterly EPS earnings growth|JUNS: Year-over-year earnings per share growth for the last twelve months|Relmada Therapeutics (RLMD) - Year-over-year earnings per share growth for the last twelve months|Earnings per share growth in annualized terms for the last twelve months annovisbio.com (ANVS)|Year-over-year earnings per share growth for the last twelve months Grace Therapeutics Inc|Firefly Neuroscience, Inc. (AIFF) - Year-over-year net earnings per share change for the last twelve months|Year-over-year earnings per share growth for the last twelve months Klotho Neurosciences Inc (KLTO)|neurosense-tx.com - Year-over-year earnings per share growth for the last 12 months|Quarterly EPS earnings growth RVPH (Reviva Pharmaceuticals)|MetaVia Inc. (MTVA) - Earnings per share growth in annualized terms for the last twelve months|NRXS: Year-over-year net earnings per share growth for the last 12 months|HSDT - Quarterly EPS earnings growth|passagebio.com (PASG) - Year-over-year earnings per share growth for the last twelve months|Neuphoria Therapeutics - Year-over-year earnings per one share growth for the last 12 months|Year-over-year earnings per share growth for the last twelve months Minerva Neurosciences|Earnings per share growth in annualized terms for the last twelve months athira.com ATHA|Quarterly EPS earnings growth ADXN|Quarterly EPS earnings growth alzamend.com (ALZN)|Quarterly EPS earnings growth CYCN (Cyclerion Therapeutics, Inc.)|PTIX - Year-over-year net earnings per share growth for the last 12 months|KTTA: Year-over-year net earnings per share growth for the last 12 months|CRGT - Quarterly EPS earnings growth|Avenue Therapeutics, Inc. (ATXI) - Year-over-year earnings per share growth for the last twelve months|Year-over-year net earnings per share growth for the last 12 months Brainstorm Cell Therapeutics Inc.|CARA (Cara Therapeutics, Inc) - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Chromocell CHRO|Year-over-year earnings per share growth for the last twelve months Eliem Therapeutics (ELYM)|intracellulartherapies.com - Year-over-year earnings per share growth for the last 12 months|Longboard Pharmaceuticals, Inc. - Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per one share growth for the last 12 months MRNS|NKGN - Year-over-year earnings per share growth for the last twelve months|Year-over-year net earnings per share trend for the last twelve months NRBO|SAGE: Quarterly EPS earnings growth|synaptogen.com - Year-over-year earnings per one share growth for the last 12 months|TRVN (Trevena) - Quarterly EPS earnings growth|Quarterly EPS earnings growth Vigil Neuro|Year-over-year earnings per share growth for the last twelve months Anew Medical, Inc. (WENA)|CERE (Cerevel Corp) - Year-over-year earnings per one share growth for the last 12 months
